[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-acute-malnutrition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-acute-malnutrition":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,77,102,136,160,183,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100640887","regular-growth-monitoring-rgm-of-young-children-in-guinea-bissau-100640887",false,"NCT07584395","Regular Growth Monitoring (RGM) of Young Children in Guinea-Bissau","Pilot Study to Assess the Benefits and Sustainability of Regular Growth Monitoring (RGM) of Young Children in Villages in Guinea-Bissau","Inclusion Criteria:\n\n* Children aged 6 months to 5 years residing in one of the two selected villages in Guinea-Bissau\n* Caregiver willing to enroll the child in the study (verbal consent provided)\n* Caregiver can provide birth certificate or documentation of child's age\n* Child does not have severe acute malnutrition (SAM) at the baseline assessment\n\nExclusion Criteria:\n\n* Children diagnosed with severe acute malnutrition (SAM) at baseline (these children will be referred to the local malnutrition clinic)\n* Children whose caregivers do not wish to participate",true,"ALL","6 Months","5 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","Wasting (severe thinness) is a common and serious problem among young children in rural Guinea-Bissau. Community Health Agents (CHAs) can help prevent malnutrition by regularly measuring children's growth and advising families on nutritious local foods. However, this practice is not consistently implemented.\n\nThis pilot study will test whether implementing Regular Growth Monitoring (RGM) by CHAs every month is feasible and effective in reducing malnutrition among children aged 6 months to 5 years in two rural villages. Investigators will also compare three methods for measuring mid-upper arm circumference (MUAC), which is used to detect malnutrition: the standard WHO tape measure, a photograph of the arm, and a simple bracelet. The goal is to identify which method is easiest for CHAs to use reliably.\n\nBaseline and final measurements will be taken in both villages. One village will receive the monthly RGM intervention first, followed by the second village. Families will also be asked about their experiences with the program through brief questionnaires.",[28,29],"Severe Acute Malnutrition","Moderate Acute Malnutrition (MAM)",[31,32,33,34,35],"Childhood malnutrition","Growth monitoring","Guinea-Bissau","Wasting","Mid-upper arm circumference","NOT_YET_RECRUITING","2026-05-07",{"date":39,"type":40},"2026-05-13","ACTUAL",{"date":42,"type":22},"2026-05-02",{"date":44,"type":22},"2026-12",{"name":46,"class":47},"Trustees of Dartmouth College","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100561662","the-decide-tb-trial-validation-of-treatment-decision-algorithms-for-childhood-tuberculosis-100561662","NCT06593080","The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis","Validation of Treatment Decision Algorithms for Childhood Tuberculosis at District Health Care Levels in Mozambique and Zambia - the Decide-TB Cluster-randomized Pragmatic Trial","DTB","Inclusion Criteria:\n\nThe effectiveness assessment will be conducted using aggregated or individual data from direct beneficiaries of the intervention:\n\n* All sick children aged below 15 years entering the selected health facilities (DH and PHC) at either outpatient (OPD) or inpatient (IPD) departments, including children from high-risk groups, as well as children identified as contact of TB cases through community- or facility-based household contact tracing.\n* Children with presumptive TB.\n\nThe WHO definition of presumptive TB will be used, as defined in the 2022 WHO Operational Handbook, namely: children are classified as having presumptive TB if they have unremitting symptoms lasting more than 2 weeks (any one of cough, fever, not eating well or anorexia, weight loss or failure to thrive, fatigue, reduced playfulness or decreased activity) .\n\nThe definitions of presumptive TB have been adapted locally for the programmatic pilot. All children with presumptive TB as defined locally will be considered in the intervention and in secondary effectiveness and sub-group analyses.\n\nHigh-risk group will be defined using the definition in WHO-suggested TDAs A\\&B as children younger than 2 years, CLHIV or children with SAM. CLHIV will be defined per national testing strategy including positive PCR test for children below the age of 18 months. Children will be considered to have SAM (and thereby be eligible for the TB-Speed SAM algorithm) using WHO criteria. These include being \\\u003C5 years with a weight-for-height Z score (WHZ) \\\u003C -3 SDs or mid-upper arm circumference (MUAC) \\\u003C 115 mm (in children over 6 months) or clinical signs of bilateral pitting oedema, and being aged ≥5 years with a body mass index (BMI) for age Z-score \\\u003C -3SD.\n\nExclusion Criteria:\n\nThere will be no exclusion criteria for the programmatic pilot: all children will be offered the intervention.","14 Years",{"count":59,"type":22},30240,[25],"The Decide-TB project aims to generate evidence for the implementation of a comprehensive Treatment Decision Algorithms (TDA) based approach for TB in children living in high TB burden and resource-limited countries, at District Hospital (DH) and Primary Health Centre (PHC) levels, and to facilitate the integration of this evidence within practices and policies.\n\nThis programmatic pilot led by the National TB Programs (NTP) will test a TDA-based approach integrating TB screening, diagnosis, treatment decision-making, and disease severity assessment for shorter treatment eligibility, for use at a lower level of healthcare. This TDA-based approach will be evaluated in a hybrid effectiveness implementation study based on a pragmatic stepped wedge cluster-randomized trial. The Decide TB project will be implemented at the district level, targeting five districts in each country. Each cluster in a district will be made up of one district hospital and six primary health centers. The study will develop a Clinical Decision Support System (CDSS) to operationalize the use of TDAs, and strengthen District Health Information Systems (DHIS2) to collect individual data, which will contribute to monitoring and evaluation, clinical mentoring, and supervision by the country's NTPs.",[63,64,65,28],"Tuberculosis","Child Health","HIV","RECRUITING","2026-03-19",{"date":69,"type":40},"2026-03-24",{"date":71,"type":40},"2024-06-01",{"date":73,"type":22},"2027-08-31",{"name":75,"class":47},"Chishala Chabala",29,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100527931","choline-to-improve-malnutrition-and-enhance-cognition-100527931","NCT06154174","Choline to Improve Malnutrition and Enhance Cognition","CHIME-SAM","Inclusion Criteria:\n\n* 6-59 months of age\n* mid-upper arm circumference \\\u003C 11.5 cm and\u002For weight-for-length z-score \\\u003C -3 and\u002For presence of bilateral pedal pitting edema\n* willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic\n\nExclusion Criteria:\n\n* features of complicated SAM: inability to tolerate a 30g test dose of RUTF, breathing difficulties, mental status changes, sepsis, or physician\u002Fnursing clinical assessment that the child needs immediate hospitalization\n* participation in a separate feeding program within the past month\n* known allergy to study food ingredient (peanut, milk, fish)\n* intention to move away from catchment area within 9 months\n* developmental delay\n* presence of a chronic severe medical condition (other than TB and HIV), such as congenital heart disease","59 Months",{"count":86,"type":22},1500,[25],"The goal of this clinical trial is to test adding choline to ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition (SAM) in Malawi. The main question it aims to answer is:\n\n\\- Will the addition of a 500mg daily dose of choline to RUTF during treatment for SAM improve cognitive development among 6-59-month-old Malawian children compared with standard RUTF without added choline?",[28,90,34,91],"Cognitive Impairment","Kwashiorkor","2026-03-16",{"date":94,"type":40},"2026-03-17",{"date":96,"type":40},"2023-12-05",{"date":98,"type":22},"2026-11",{"name":100,"class":47},"Washington University School of Medicine",10,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":101},"100582940","milk-fat-globule-membrane-enhanced-rutf-for-children-with-severe-acute-malnutrition-100582940","NCT06869850","Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition","MFGM-EnhaNceD RUTF for Children With SAM","MEND-SAM","Inclusion Criteria:\n\n* 6-59 months of age\n* Reside within the catchment area of a participating clinic\n* mid-upper arm circumference \\\u003C 11.5 cm and\u002For weight-for-length z-score \\\u003C -3 and\u002For presence of bilateral pedal pitting edema\n* willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic\n\nExclusion Criteria:\n\n* Features of complicated SAM: inability to tolerate a 30 g test dose of RUTF, breathing difficulties, mental status changes, sepsis, diarrhea with severe dehydration, and\u002For physician\u002Fnursing clinical assessment that the child needs immediate hospitalization\n* Participation in a separate therapeutic feeding program within the past month\n* Known allergy to study food ingredient (peanut, milk, fish)\n* Clinically evident developmental delay (most often determined based on research nursing assessment of physical appearance, movement, and informal discussion with caregiver)\n* Presence of a chronic severe medical condition (other than tuberculosis and HIV), such as congenital heart disease",{"count":111,"type":22},1600,[25],"The goal of this clinical trial is to test the use of milk fat globule membrane (MFGM) in ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition in Sierra Leone. The main questions it aims to answer are:\n\n* Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition improve their neurodevelopment?\n* Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition reduce its worst consequences: death, hospitalization, and remaining severely malnourished despite treatment?\n\nResearchers will compare the MFGM-containing RUTF to standard RUTF, which contains skim milk powder.\n\nParticipants will:\n\n* undergo measurement of length, weight, mid-upper arm circumference, and nutritional edema assessment every two weeks during severe malnutrition treatment\n* be treated with either MFGM-RUTF or standard RUTF at a dose of 2 sachets per day for up to 12 weeks\n* undergo neurodevelopmental testing using the Malawi Developmental Assessment Tool at the end of SAM treatment and 6 months later\n* a subset of participants will undergo blood spot collection and stool sample collection",[28,90,91,115],"Severe Wasting",[117,118,119,120,121,122,123,124,125,126,127],"severe acute malnutrition","severe wasting","kwashiorkor","milk fat globule membrane","neurodevelopment","phospholipids","ganglioside","dairy fat","malawi developmental assessment tool","Sierra Leone","ready-to-use therapeutic food","2025-12-16",{"date":130,"type":40},"2025-12-17",{"date":132,"type":40},"2025-09-22",{"date":134,"type":22},"2027-12-01",{"name":100,"class":47},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":48},"100516913","phase-4-azithromycin-as-adjunctive-treatment-for-uncomplicated-severe-acute-malnutrition-100516913","NCT06010719","Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition","Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition: the AMOUR Trial","AMOUR","Children with uncomplicated SAM per Burkina Faso's national guidelines who present to an eligible enrollment site during the study period and meet all of the eligibility criteria below will be considered for enrollment:\n\nInclusion criteria:\n\n* Age 6-59 months\n* WHZ\\\u003C-3 SD or MUAC\\\u003C115 mm\n* Primary residence within a catchment area of an enrollment site\n* Available for full 8-week study (primary endpoint)\n* Not admitted to a nutritional program for SAM treatment in the previous 2 weeks\n* No edema\n* No antibiotic use in the past 7 days\n* No clinical complications requiring antibiotic or inpatient treatment\\*\\*\n* No congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of SAM treatment benefit (such as cerebral palsy, Down syndrome, congenital heart disease, cleft lip\u002Fpalate, etc)\n* No known allergies to macrolides\u002Fazalides or amoxicillin\u002Fpenicillin\n* Sufficient appetite according to a feeding test with RUTF\n* Written informed consent from at least one parent or guardian\n\nExclusion criteria:\n\n* Age less than 6 month or more than 59 months\n* WHZ\\>-3 SD or MUAC\\>115 mm\n* Primary residence is not within a catchment area of an enrollment site\n* Not Available for full 8-week study (primary endpoint)\n* Admitted to a nutritional program for SAM treatment in the previous 2 weeks\n* Edema\n* Antibiotic use in the past 7 days\n* Clinical complications requiring antibiotic or inpatient treatment\\*\\*\n* Congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of SAM treatment benefit (such as cerebral palsy, Down syndrome, congenital heart disease, cleft lip\u002Fpalate, etc)\n* Known allergies to macrolides\u002Fazalides or amoxicillin\u002Fpenicillin\n* No Sufficient appetite according to a feeding test with RUTF\n* No Written informed consent from at least one parent or guardian\n\n  * Per Burkinabé guidelines, children any of the following conditions will not be eligible for the trial and will be referred to an inpatient facility: MUAC \\\u003C115 mm with complications; MUAC \\\u003C115 mm plus edema; bipedal pitting edema; anorexia or no appetite for RUTF; diarrhea and dehydration; unable to ingest anything without vomiting; severe pneumonia; open cutaneous lesions; hypothermia (35\\*C); fever (38.5\\*C); paleness suggesting severe anemia; hypoglycemia; very weak, lethargic, or unconscious; convulsions; signs of vitamin A deficiency; or a condition requiring IV infusion or an NG tube.",{"count":145,"type":22},3000,[147],"PHASE4","Amoxicillin is recommended by the World Health Organization (WHO) as adjunctive therapy for the treatment of uncomplicated severe acute malnutrition (SAM). Because children with uncomplicated SAM may have asymptomatic infection due to immune suppression, presumptive treatment with a broad-spectrum antibiotic may be beneficial by clearing any existing infection and improving outcomes. Two randomized placebo-controlled randomized trials have evaluated amoxicillin for uncomplicated SAM and have found conflicting results. These results may indicate either that antibiotics are not helpful for the management of uncomplicated SAM, or that a better antibiotic is needed. Recently, the investigators demonstrated that biannual mass azithromycin distribution as a single oral dose reduces all-cause child mortality in sub-Saharan Africa. Children with uncomplicated SAM, who have an elevated risk of mortality relative to their well-nourished peers, may particularly benefit from presumptive azithromycin treatment. Our pilot data demonstrated feasibility in rapid enrollment of children with uncomplicated SAM in our study area, and showed no significant difference between azithromycin and amoxicillin, demonstrating equipoise for a full-scale trial. Here, the investigators propose an individually randomized trial in which children will be randomized to a) azithromycin, b) amoxicillin, or c) placebo, and evaluated for differences in weight gain, nutritional recovery, and the gut microbiome. The results of this study will strengthen the evidence base for policy related to the use of antibiotics as part of the management of uncomplicated SAM, including additional evidence of amoxicillin versus placebo as well as evaluation of an antibiotic class that has not been considered for uncomplicated SAM, which may lead to changes in guidelines for treatment.",[150,28],"Malnutrition, Child","2025-10-13",{"date":153,"type":40},"2025-10-15",{"date":155,"type":40},"2024-10-23",{"date":157,"type":22},"2028-12-29",{"name":159,"class":47},"University of California, San Francisco",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100520816","modified-dosage-for-severe-acute-malnutrition-100520816","NCT06061484","Modified Dosage for Severe Acute Malnutrition","Safety Efficacy, and Cost-effectiveness of Modified Doses of Ready-to-use Therapeutic Food for the Treatment of Severe Acute Malnutrition Among Children 6-59 Months of Age in Ethiopia","MODAM-SAM","Inclusion Criteria:\n\n1. Age 6-59 months\n2. Reside in the catchment area of the health post where the trial is to be conducted without plans to leave the area over the next year\n3. Uncomplicated severe acute malnutrition, as defined by no signs of severe illness that would require referral to inpatient facility\n4. Pass appetite test conducted at the time of enrollment\n5. Consent for randomization into the study given by mother, father, and\u002For other primary caregiver\n6. Mid-upper arm circumference less than 115 mm and\u002For nutritional edema\n7. Weight-for-height Z-score (WHZ) less than -3\n\nExclusion Criteria:\n\n1. Complicated acute malnutrition with severe illness requiring transfer to a stabilization center or hospital for treatment. This includes, but is not limited to: a. Hypothermia b. High fever c. Signs of hypoglycemia d. Lethargy or altered mental status e. Moderate to severe dehydration f. Shock g. Other medical complications requiring hospitalization or higher-level medical evaluation\n2. Treatment for acute malnutrition, either as an inpatient or outpatient, within the past 3 months\n3. Known chronic medical illness such as severe cerebral palsy, severe congenital anomalies such as unrepaired congenital heart disease, Down syndrome, hydrocephalus, unrepaired cleft lip or palate, or other conditions that would be expected to contribute to difficulty feeding the prescribed amounts of therapeutic or supplementary food",{"count":169,"type":22},2400,[25],"Protocols for the community-based management of acute malnutrition (CMAM) have not changed significantly for more than 20 years, with relatively complex treatment protocols and persistent supply chain challenges that have limited overall program coverage, leaving millions of malnourished children without care annually. The overarching goal of this research project is to simultaneously test two novel simplified approaches in CMAM with potential to improve program coverage. The simplified approach includes two parallel clinical trials for SAM and MAM treatment. Two fixed-dose regimes of RUTF will be tested against the current weight-based dosing of RUTF for children with SAM.",[28],"2024-07-15",{"date":175,"type":40},"2024-07-16",{"date":177,"type":40},"2023-09-25",{"date":179,"type":22},"2026-09-25",{"name":181,"class":47},"Action Against Hunger USA",3,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":200,"locationsCount":182},"100519017","family-mid-upper-arm-circumference-muac-follow-up-after-recovery-from-acute-malnutrition-modam-fmuac-100519017","NCT06038071","Family Mid-Upper Arm Circumference (MUAC) Follow-up After Recovery From Acute Malnutrition (MODAM-fMUAC)","Efficacy and Safety of Family Mid-upper Arm Circumference (MUAC) After Recovery From Severe and Moderate Acute Malnutrition","MODAM-fMUAC","Inclusion Criteria:\n\n* children 6-59 months of old who recovered from SAM or MAM following treatment in either the MODAM-SAM or MODAM-MAM trials\n\nExclusion Criteria:\n\n* caregiver not planning on remaining in the local area for the subsequent 6 months",{"count":192,"type":22},3600,[25],"Protocols for the community-based management of acute malnutrition (CMAM) have not changed significantly for more than 20 years, with relatively complex treatment protocols and persistent supply chain challenges that have limited overall program coverage, leaving millions of malnourished children without care annually. The overarching goal of this research project is to simultaneously test two novel simplified approaches in CMAM with potential to improve program coverage. The simplified approach includes two parallel clinical trials for SAM and MAM treatment. For the Family MUAC follow-up study, children who recover from these two parallel clinical trials will be enrolled in trial to test the effectiveness of MUAC screening at home by the child's caregivers as a self-referral strategy, compared to a scheduled health facility-led strategy and the standard of care of community-based follow-up visits.",[28,196],"Moderate Acute Malnutrition",{"date":175,"type":40},{"date":177,"type":40},{"date":179,"type":22},{"name":181,"class":47},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":48},"100539823","microbiota-directed-food-for-children-with-severe-acute-malnutrition-100539823","NCT06308848","Microbiota Directed Food for Children With Severe Acute Malnutrition","Proof-of-Concept Study for a Microbiota-Directed Food in Children With Uncomplicated Severe Acute Malnutrition in Rural Bangladesh","Inclusion Criteria:\n\n* The trial will include SAM children of either sex without any medical complication\n* Children aged between 6-\\\u003C24 months and with MUAC \\\u003C115 mm and\u002For WLZ \\\u003C-3\n\nExclusion Criteria:\n\n* Children are not suffering from SAM.\n* Children with bi-pedal oedema.\n* Failed to obtain consent for study participation from parents or legal guardian.\n* Suffering from any chronic illness(es) or having severe anemia (\\\u003C 8 g\u002Fdl).\n* History of using antibiotics in the past seven days.\n* Children participating in other food intervention programs.\n* Children having known history of soy, peanut or milk protein allergy.\n* Children who will not pass appetite test.","24 Months",{"count":210,"type":22},256,[25],"Severe acute malnutrition (SAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing SAM is crucial to prevent its progression to other childhood morbidity and mortality and to ensure healthy child development. To meet the nutritional requirement of SAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use therapeutic food. The investigators propose this proof-of-concept trial to establish evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with SAM in comparison to the standard RUTF.",[28],[215,216,217,218],"Microbiota directed food","SAM","Gut microbiota","Bangladesh","2024-03-11",{"date":221,"type":40},"2024-03-13",{"date":223,"type":22},"2024-04-15",{"date":225,"type":22},"2026-12-31",{"name":227,"class":47},"International Centre for Diarrhoeal Disease Research, Bangladesh"]